Palabras Clave
quiste óseo aneurismático (MeSH ID: D017824) - denosumab (ID MeSH: 000069448) - revisión
de la literatura (MeSH ID: D003211)
Introduction
Aneurysmatic bone cysts (ABCs) are considered locally-aggressive benign tumors with
a significant potential for recurrence.[1]
[2]
They represent approximately 1% of all bone tumors, with an incidence of 0.14 per
100 thousand inhabitants. Approximately 75% to 90% of the cases occur before the age
of 20. The most common sites are the long bones (67%), the spine (15%), and the pelvis
(9%).[3]
[4]
Regarding pathophysiology, evidence shows genetic alteration, specifically a positive
regulation induced by translocation of the ubiquitin-specific peptidase 6 (USP6) gene located at chromosome 17p13, which favors a primary neoplastic process. This particular translocation increases
TRE17 production, a protease that leads to an increase in metalloproteinase in the matrix
and in the activity of matrix metalloproteinase-10 (MMP-10). This is associated with
a block in osteoblast maturation through an autocrine mechanism and increased release
of vascular endothelial growth factor (VEGF), thus increasing vascularization.[1]
[4]
Clinically, it usually presents as a simple lesion associated with a mass that increases
in volume over time, edema, and pain. Histopathologically, the tumor is characterized
by the formation of a cavity that contains uncoagulated blood and is divided by septations
of fibrous connective tissue comprising a mixture of components, including multinucleated
giant cells, osteoclasts, and fibroblast-like stromal cells.[3]
Multiple treatments are described, such as: intralesional excision, selective arterial
embolization, injection of sclerosing agents, and radiation. These treatments have
a variable rate of efficacy, since recurrence can reach 20% and can be associated
with serious comorbidities such as functional loss of the limb.[3]
[5]
A recent study[6] suggests that the pathophysiology of ABC is similar to that of giant-cell tumors
(GCTs) of the bone. In the TCG, malignant cells secrete the receptor activator of
nuclear factor kappa-B ligand (RANKL).
Denosumab is a human monoclonal antibody that binds specifically to RANKL. This prevents
activation of osteoclast receptor activator of nuclear factor kappa-B (RANK) by inhibiting
its function. This drug is highly effective in GCT of the bone and, in principle,
similar effects can be expected in ABC. It is important to know that today there is
no treatment protocol or recommendation for the use of denosumab in ABC.[1]
The present article aims to review the literature on the use of denosumab for the
treatment of ABC, describing the epidemiological profile, the dosage, and the complications.
Methodology
On the PubMed database, we retrieved articles published in the last five years with
the following keywords: ANEURYSMAL BONE CYST AND DENOSUMAB.
Case reports, case series, and clinical trials regarding any bone segments and patients
of any age were used as inclusion fcriteria.
Articles regarding other tumors were excluded.
The information collected from the cases was age, gender, tumor location, the performance
of surgery before and/or after the treatment with denosumab, the dose used, the complications,
and recurrence.
Results
Using the keywords and the 5-year period, 31 articles were found. When using the inclusion
and exclusion criteria, eight articles remained. As one article presented preliminary
results, it was excluded from the research. In the end, 7 articles remained: 4 case
reports and 3 case series, all written in English and published from 2014 to 2019.
There was a total of 24 (11 male and 13 female) patients with an average age of 14
(range: 5–35) years.
The most frequent location was the spine (45.8%), followed by the long bones (20.8%),
and the pelvis (20.8%). In one case, the article did not report the location.
In total, 54% of the patients did not undergo surgery before the denosumab treatment.
As for those submitted to surgery, the majority (36%) underwent curettage plus bone
grafting.
In total, 5 articles used the same treatment protocol as that used for GCT of the
bone, that is, subcutaneous (SC) administration of denosumab at a dose of 120mg on
days 1, 8, 15 and 28 in the first month, followed by a monthly application of 120 mg
until clinical and radiological resolution. In the article by Kurucu et al.[3] (2018), the protocol used was the weekly SC administration of denosumab at a dose
of 70 mg/m2 during the first month, and then monthly, until clinical and radiological resolution.[3] In the article by Ntalos et al.[7] (2017), the protocol used was the monthly SC administration of denosumab at a dose
of 60 mg until clinical and radiological resolution, as it would decrease the risk
of side effects such as hypocalcemia. In all studies except the one by Ntalos et al.,[7] supplementation with calcium and vitamin D to avoid hypocalcemia was performed.
Most patients (66.7%) did not require surgical treatment after using denosumab. In
the cases submitted to surgery, the majority (62.5%) underwent curettage.
Regarding recurrence, most patients (66.7%) did not present this complication. In
cases that presented the complication, 50% were treated with another period of denosumab.
It is noteworthy that in two patients the monthly administration of 120 mg of the
medication was maintained until the end of the study.
Another reported complication was hypercalcemia as a rebound effect after the discontinuation
of denosumab, which occurred in 3 (12.5%) patients.
Discussion
Though benign, ABCs are locally-aggressive tumors. Wide resections with an oncological
margin can lead to major defects, serious complications, and, in some patients, they
are contraindicated due to the location of the tumor. Intralesional curettage with
or without bone grafting is the therapy predominantly used, but it carries a 20% risk
of local recurrence.[1] Some authors[4] advise using phenol as an adjuvant, as the recurrence rate drops to 7%.
To reduce these complications with extensive resections, less invasive methods have
been developed, such as: cryotherapy, sclerotherapy, doxycycline injections, radionucleotide
ablation, arterial embolization, and radiotherapy. Good results have been reported,
but the recurrence rate remains a problem.[7]
In GCT of the bone, the interaction between RANK and RANKL is an important factor
that regulates the formation of giant cells and tumor progression. Denosumab effectively
blocks the RANK–RANKL interaction, and has been approved for the treatment of osteoporosis,
bone metastases, multiple myeloma, and GCT of the bone. The pathophysiology of ABC
is similar to that of GCT of the bone, and the use of denosumab in ABC was first reported
in 2013 in a study by Lange et al.[8]
The present research showed a slight predominance of females with an average age in
their teens. The most common location was the spine, which is different from what
is reported in the literature, probably because the articles used in the present review
did not show an indication of resection with an oncological margin, and ABC located
in the spine constitutes a challenge in terms of treatment, since it requires treatment
with low rates of sequelae and recurrences.
The present research showed that just over half of the patients underwent surgical
treatment before the administration of denosumab; therefore, one of the indications
for the use of the drug is tumor recurrence.
As reported by Dürr et al.[1] (2019), so far there is no protocol or treatment recommendation for the use of denosumab
in ABC, so the strategy employed is the same as the one for GCT of the bone, that
is, SC administration of 120mg (or 70mg/m2) of denosumab on days 1, 8, 15 and 28 in the first month, and after that, the monthly
SC administration of 120mg (or 70mg/m2). Calcium at a dose of 500mg and vitamin D at a dose of 1000IU were prescribed for
daily use. This strategy was used in 6 articles, except in the study by Ntalos et
al.[7] (2017), who administered 60 mg SC monthly and did not mention supplementation with
calcium and vitamin D. The authors reported that they decided to evaluate the therapeutic
effect and reduce the potential side effect. In this report, the patient received
denosumab and then underwent the curettage surgery plus bone graft; the patient evolved
with recurrence, and the medication was restarted following the same schedule for
a 17-month period before surgery. Then, the patient evolved with no signs of tumor
recurrence, but showed signs of osteoporosis and low levels of calcium, phosphate,
and 25-hydroxyvitamin D3 combined with high levels of parathyroid hormone (PTH).[7]
The main complication found was recurrence in 80% of the cases. Half of the cases
were submitted to a new denosumab regimen. Only two patients continued using denosumab
until the end of the study due to a history of several recurrences.[1] The conclusion of all articles in the present research is that none of the patients
showed signs of ABC recurrence.
Another reported complication was hypercalcemia as a rebound effect after the discontinuation
of Denosumab, which occurred in 3 (12.5%) patients. Unlike adults and apparently quite
common in patients under 10 years of age, rebound hypercalcemia has been reported
3 to 4 months after the last dose of Denosumab.[4] The 3 cases in the study were younger than 10 years of age.
The other complications described in the literature are hypocalcemia, jaw necrosis,
fatigue, muscle pain and atypical femoral fracture.[1]
With the present research, we have noticed that the negative points are the low number
of patients and the lack of protocols regarding dosage, treatment time, and when to
use a neoadjuvant, an adjuvant, or both.
Conclusion
The present research has shown that the use of denosumab for ABC treatment yielded
good results because it has low rates of recurrence and complications. However, further
studies are needed to define the treatment protocol.
